Oncology Practice Valuation: Drug Revenue, Payers and EBITDA
An oncology practice valuation is unlike a valuation for most physician practices. Large drug revenue, thin and changing drug margins, heavy Medicare exposure and expensive equipment can make two practices with similar collections worth very different amounts.
Whether you are preparing to sell, planning to bring in a partner or evaluating a purchase, understanding what drives value can help you set expectations and prepare for lender review. This article is general education. Valuation methods vary by appraiser and transaction, reimbursement rules vary by payer, and nothing here is legal, tax, billing or compliance advice.
Why Gross Revenue Can Mislead
In many community oncology practices, a large share of collections comes from drugs administered in the office. The practice buys those drugs, administers them and bills payers afterward. Because drug costs pass through the income statement, gross revenue may look large while the margin retained by the practice is far smaller.
A buyer, lender or appraiser will generally focus on what remains after drug costs, staffing and overhead. Two practices with similar top-line revenue can produce very different earnings depending on their drug mix, purchasing terms and payer contracts.
What Normalized EBITDA Means in Oncology
Most valuations start with earnings before interest, taxes, depreciation and amortization, adjusted to reflect how the practice would perform under a new owner. Typical normalizing adjustments include:
- Physician compensation: replacing owner pay with a market salary for the work performed
- One-time expenses: unusual legal costs, a single large repair or a non-recurring project
- Personal expenses: owner-related costs run through the practice
- Related-party rent: adjusting rent paid to an owner-controlled entity to a market rate
- Drug inventory timing: recognizing swings in purchases that distort a single year
Every add-back should be documented. Lenders and buyers will generally discount adjustments they cannot verify.
Payer Mix and Reimbursement Risk
Many oncology practices depend heavily on Medicare, both for professional services and for drugs covered under Part B. Changes to drug payment rules, physician fee schedules or site-of-care policies can affect future earnings, so valuations often weigh how exposed a practice is to those changes.
Commercial payer contracts matter too. A practice with favorable, stable commercial agreements may be viewed differently than one dependent on a single insurer. Our article on oncology practice payer mix looks at how lenders weigh Medicare concentration.
Service Lines That Affect Oncology Practice Valuation
Beyond infusion, many practices have ancillary services that can add or subtract value depending on their profitability and stability:
- In-office dispensing of oral cancer drugs
- Laboratory and pathology services
- Diagnostic imaging, including PET/CT
- Radiation oncology and associated equipment
- Participation in value-based payment models
Each service should be reviewed on its own. Ancillaries may rely on specific regulatory structures, and their ongoing viability should be reviewed by healthcare counsel and qualified compliance professionals rather than assumed.
Owner Dependence and Physician Retention
An oncology practice is built on long-term patient relationships and referral networks with surgeons, primary care physicians and hospitals. If one physician manages a large share of patients and plans to leave soon after a sale, value may be reduced.
Buyers and appraisers generally look at physician ages and retirement plans, the depth of the advanced practice provider team, infusion nurse retention and whether key physicians will sign employment agreements after the transaction. Restrictive covenants should be reviewed by counsel because enforceability varies by state.
Market Forces and Competing Buyers
Hospitals, oncology networks and private equity groups may all have interest in a well-run community practice, and each may value it differently. Hospitals with access to drug pricing programs may see value a physician buyer cannot capture. Our article on 340B oncology practices explains why that program shapes acquisition activity.
A physician buyer, by contrast, is generally limited to what the practice’s own cash flow can support. That is the lens lenders use. When a practice is being sold to an internal partner or an outside physician, the price must work with financing the practice can service.
Tangible Assets: Equipment, Inventory and Real Estate
Oncology practices may hold valuable equipment, drug inventory and sometimes the building itself. Buyers will usually want to know:
- Whether drug inventory is included in the price or purchased separately at closing
- The age and condition of infusion chairs, pumps, imaging and radiation equipment
- Existing equipment leases and loans that must be paid off or assumed
- Whether the real estate is owned by the practice, the physicians or a third party
How these items are handled can change both the purchase price and the financing structure.
How Lenders Use the Valuation
When a buyer finances an acquisition, the lender will generally review the valuation alongside historical cash flow, the buyer’s experience and the proposed structure. The lender’s question is whether the practice can support debt service after paying the new owner a reasonable salary. Every loan is subject to approval, and nothing here is a commitment to lend.
If you are on the buying side, our guide to how to buy an oncology practice covers the financing steps. If you are considering an exit, our article on how to sell an oncology practice compares buyer types.
Preparing for an Oncology Practice Valuation
Owners can make the process smoother by gathering several years of financial statements and tax returns, revenue by payer and by service line, drug purchasing records, accounts receivable aging, equipment lists and lease agreements. Clean records may support a stronger, more defensible result.
Final Thoughts
A credible oncology practice valuation separates drug pass-through revenue from true earnings, weighs payer and reimbursement exposure and accounts for physician retention and tangible assets. Owners who understand these drivers early can make better decisions about selling, adding partners or planning succession.
US Medical Funding helps oncology practice owners and buyers plan transactions and finance acquisitions. Learn more about our advisory and consulting services, our oncology practice acquisition financing and our full range of oncology practice financing options.
